Voyager Therapeutics Inc is a biotechnology company that leverages human genetics to modify the course of and ultimately cure neurological diseases. The company focuses on developing gene therapies and other genetic medicines for conditions such as Alzheimer disease Friedreich ataxia Parkinson disease and other central nervous system disorders. Its flagship technology is the TRACER tropism redirection of AAV by cell type specific expression of RNA platform which enables discovery of adeno associated virus capsids capable of crossing the blood brain barrier and achieving high brain exposure after intravenous dosing. Voyager Therapeutics advances a wholly owned pipeline that includes a tau silencing gene therapy candidate VY1706 and an anti tau antibody candidate VY7523 both targeting Alzheimer disease. It also pursues collaborative programs with partners such as Neurocrine Biosciences Novartis Alexion and Transition Bio to address Friedreich ataxia glucocerebrosidase beta 1 related disorders Huntington disease spinal muscular atrophy amyotrophic lateral sclerosis and frontotemporal dementia. The company's research efforts are supported by a suite of patents and patent applications covering capsid design receptor mediated transport and therapeutic payloads.

Voyager Therapeutics generates revenue primarily through upfront payments development milestones and royalty payments from collaboration and licensing agreements with pharmaceutical partners. To date the company has received more than $500 million in non dilutive funding from these agreements including an upfront payment of $136 million from Neurocrine Biosciences an upfront payment of $80 million from Novartis and an upfront payment of $30 million from Alexion. In addition Voyager Therapeutics is eligible to receive up to $6.8 billion in future milestone payments across its partnered portfolio comprising up to $2.4 billion in development milestones up to $1.5 billion in sales milestones and the remainder in royalties. The company does not currently commercialize any products and therefore has no product sales revenue.

Voyager Therapeutics occupies a niche in the biotechnology industry as a developer of proprietary adeno associated virus capsids and delivery platforms that enable intravenous administration of genetic medicines to the brain. Its TRACER platform and the derived Voyager NeuroShuttle technology provide a competitive edge by achieving broad brain exposure after a simple vein injection a capability that many competitors achieve only through invasive routes such as intrathecal or intracerebral delivery. The company faces competition from large pharmaceutical firms such as Biogen Eisai and Roche as well as from specialized biotechs including 4D Molecular Therapeutics Affinia Therapeutics Sarepta Therapeutics and Ultragenyx Pharmaceutical that are also pursuing adeno associated virus based therapies and blood brain barrier crossing technologies. Additional competitors include academic groups and government laboratories that work on gene therapy vectors neuroprotective small molecules and antisense oligonucleotides for neurologic disorders. Voyager Therapeutics believes its differentiation stems from its deep expertise in neurogenetics its proprietary TRACER capsid discovery process and its growing patent portfolio which includes at least 92 issued patents and more than 359 pending patent applications in the United States and abroad. These assets cover areas such as adeno associated virus engineering antibody formulation non viral transport mechanisms and disease specific targets like tau and glucocerebrosidase. Together these factors give the company a distinct position in the race to deliver effective therapies for devastating neurological conditions.

Voyager Therapeutics serves primarily pharmaceutical and biotechnology firms that collaborate with the company to develop and commercialize gene therapy products. Its key collaborators include Neurocrine Biosciences with whom it co develops programs for Friedreich ataxia and glucocerebrosidase beta 1 related disorders Novartis which licenses TRACER capsids for spinal muscular atrophy and Huntington disease programs Alexion which holds an exclusive license for a rare neurological disease target and Transition Bio which is working on small molecule therapies for amyotrophic lateral sclerosis and frontotemporal dementia. These partnerships provide the company with upfront funding milestone payments and potential royalties while allowing it to retain participation rights in many of the programs and to share in future commercial successes. Because Voyager Therapeutics has not yet launched any approved therapies it does not have a direct consumer base or traditional product customers such as hospitals or pharmacies. Instead its revenue comes from the milestones royalties and equity investments generated through its collaboration agreements.